IUSM’s Precision Health Initiative is first recipient of Grand Challenges funds
June 23, 2016
IU announced this week that the Precision Health Initiative, a research endeavor focused on patient-centered precision medicine therapies and led by IU School of Medicine faculty, will receive the first funding under the university’s new $300 million Grand Challenges Program.
The Precision Health Initiative will develop IU’s expertise in individualized precision medicine with team members working closely with several prominent business and community partners, including Eli Lilly and Company, Roche Diagnostics, Cook Regentec, Deloitte, Regenstrief Institute, and Indiana University Health.
IU President Michael A. McRobbie said the Precision Health Initiative is a visionary proposal that fully realizes the vision of IU’s Bicentennial Strategic Plan to improve the education, health, economy, and quality of life of the people of Indiana. Led by IU Associate Vice President for Clinical Affairs and IU School of Medicine Executive Associate Dean for Research Affairs Anantha Shekhar, the Precision Health Initiative will seek to cure at least one cancer and one childhood disease, as well as find ways to prevent one chronic illness and one neurodegenerative disease.
“Precision health and person-centered approaches to patient care will be the next paradigm shift for health care delivery, and likely the dominant new forces in training the next generation of graduates from health sciences schools,” Shekhar said. “The goal of precision medicine is to get the right prevention or treatment to the right patient at the right time, and this initiative will enable us to do that for Hoosiers across the state.”
To read more about the Grand Challenges and the Precision Health Initiative, visit MedNet. To view a video about the Precision Health Initiative and its goals, click here. You can also visit the IU School of Medicine website for ongoing information and developments about this project.